Cargando…

Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis

BACKGROUND: Primary breast cancer (BC) has shown a higher immune infiltration than the metastatic disease, justifying the optimal scenario for immunotherapy. Recently, neoadjuvant chemotherapy (NAC) combined with immune checkpoint inhibitors has demonstrated a gain in pathological complete responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santisteban, Marta, Solans, Belén Pérez, Hato, Laura, Urrizola, Amaia, Mejías, Luis Daniel, Salgado, Esteban, Sánchez-Bayona, Rodrigo, Toledo, Estefanía, Rodríguez-Spiteri, Natalia, Olartecoechea, Begoña, Idoate, Miguel Angel, López-Díaz de Cerio, Ascensión, Inogés, Susana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721381/ https://www.ncbi.nlm.nih.gov/pubmed/34987618 http://dx.doi.org/10.1177/17588359211064653

Ejemplares similares

Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies
por: Mejías Sosa, Luis, et al.
Publicado: (2023)

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
por: Soldevilla, Mario Martínez, et al.
Publicado: (2016)

Binge Drinking and Risk of Breast Cancer: Results from the SUN (‘Seguimiento Universidad de Navarra’) Project
por: Sánchez-Bayona, Rodrigo, et al.
Publicado: (2020)

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
por: Inogés, Susana, et al.
Publicado: (2017)

Minimally invasive tumor bed implant (MITBI) and peri-operative high-dose-rate brachytherapy (PHDRBT) for accelerated minimal breast irradiation (AMBI) or anticipated boost (A-PHDRBT-boost) in breast-conserving surgery for ductal carcinoma in situ
por: Morales, Marta Gimeno, et al.
Publicado: (2020)

C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d
por: Kowalska, Daria, et al.
Publicado: (2022)

CD28 Aptamers as Powerful Immune Response Modulators
por: Pastor, Fernando, et al.
Publicado: (2013)

“What medical students with better academic results do: a cross-sectional analysis”
por: Urrizola, Amaia, et al.
Publicado: (2023)

Two-dimensional power Doppler-three-dimensional ultrasound imaging of a cesarean section dehiscence with utero-peritoneal fistula: a case report
por: Royo, Pedro, et al.
Publicado: (2009)

Endometriosis in a postmenopausal woman without previous hormonal therapy: a case report
por: Manero, Manuel García, et al.
Publicado: (2009)

Thrombospondin-1 serum levels do not correlate with pelvic pain in patients with ovarian endometriosis
por: Manero, Manuel García, et al.
Publicado: (2009)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
por: Soldevilla, Mario Martínez, et al.
Publicado: (2017)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma
por: Casales, Erkuden, et al.
Publicado: (2021)

The value of minilaparotomy for total hysterectomy for benign uterine disease: A comparative study with conventional Pfannenstiel and laparoscopic approaches
por: Royo, Pedro, et al.
Publicado: (2009)

Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance
por: Maia, Catarina, et al.
Publicado: (2020)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)
por: Falcon, Silvia, et al.
Publicado: (2022)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
por: Aparicio, Belén, et al.
Publicado: (2021)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
por: Snoj, Natasa, et al.
Publicado: (2009)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Predictors of successful neoadjuvant treatment in HER2‑positive breast cancer
por: Hännikäinen, Elli-Noora, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7adclfna3se3fjdgb3dmeeh29p